Last checked at 
LONDON, Nov 5 (Reuters) - European drug regulators havefound no safety concerns linking GlaxoSmithKline's andMerck's cervical cancer vaccines with two conditionsknown as complex regional pain syndrome (CRPS) and posturalorthostatic tachycardia syndrome (POTS).
Concluding a safety review on Wednesday, the EuropeanMedicines Agency said its Pharmacovigilance Risk AssessmentCommittee (PRAC) found that "evidence does not support a causallink between the vaccines and development of CRPS or POTS".
"There is no reason to change the way the vaccines are usedor amend the current product information," it said in astatement.
The vaccines - GSK's Cervarix and Merck's Gardasil, - aregiven to girls and young women protect them from cervical cancercaused by the human papillomavirus (HPV) and other HPV-relatedcancers and pre-cancerous conditions.
More than 80 million girls and women worldwide have nowreceived these vaccines, and in some European countries theyhave been given to 90 percent of the age group recommended forvaccination, according to the European agency.
It said use of the vaccines is expected to prevent manycases of cervical cancer, which is responsible for tens ofthousands of deaths in Europe each year, as well as othercancers and conditions caused by HPV.
"The benefits of HPV vaccines ... continue to outweigh theirrisks," it said. "The safety of these vaccines, as with allmedicines, will continue to be carefully monitored." (Reporting by Kate Kelland; Editing by Mark Potter)
